FierceBiotechOriginal article
{"a":[{"_":"Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update","$":{"href":"/biotech/takedas-zasocitinib-proves-top-notch-difficult-treat-psoriasis-phase-3-update","hreflang":"en"}}]}
Phase 3positivezasocitinibPositive
AI Analysis
Summary
Takeda's zasocitinib demonstrated positive phase 3 results for psoriasis, with 75% of patients achieving clear or almost clear scalp psoriasis with once-daily dosing.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
75% of patients achieved clear or almost clear scalp psoriasis
Importance:7/10
Sentiment:
0.80
phase 3psoriasisdermatologypositive dataonce-daily oral
Related Companies
Read the original article
Published by FierceBiotech on July 16, 2026 10:18 AM